2019
DOI: 10.1093/rheumatology/key287
|View full text |Cite
|
Sign up to set email alerts
|

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis

Abstract: To facitinib and baricitinib are two of the currently available Janus kinase (JAK) inhibitors for the treatment of patients with RA. Randomized controlled trials have shown that these JAK inhibitors are as efficacious as biological DMARDs. Safety profiles of these JAK inhibitors in randomized controlled trials and their long-term extension studies have been demonstrated; however, real world evidence remains to be established to bridge the gap between randomized controlled trials and rheumatology clinics. Funda… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
137
0
7

Year Published

2020
2020
2022
2022

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 186 publications
(147 citation statements)
references
References 55 publications
3
137
0
7
Order By: Relevance
“…Screening for risk factors for LIP (eg, history of diverticulitis) is advised before initiating IL-6Ri 117. More long-term observational studies (with a proper comparator) are needed to clarify the risk of LIP with JAKi seen in previous pooled analyses of trial data 118–120…”
Section: Discussionmentioning
confidence: 99%
“…Screening for risk factors for LIP (eg, history of diverticulitis) is advised before initiating IL-6Ri 117. More long-term observational studies (with a proper comparator) are needed to clarify the risk of LIP with JAKi seen in previous pooled analyses of trial data 118–120…”
Section: Discussionmentioning
confidence: 99%
“…Serious infection was found to be increased with tofacitinib in the induction trials for UC, but similar across treatment groups including placebo in the maintenance trial 91 . Of 4789 patients treated with tofacitinib in phase II, III and LTE studies, 259 patients had serious infections (3.09 events per 100 PY [95% CI 2.73, 3.49]), and the most common infection was pneumonia 92 . Higher doses of 10 mg twice daily as opposed to 5 mg twice daily, age >65 years, corticosteroids >7.5 mg/d and diabetes were also independent factors associated with increased serious infection risk 92,93 .…”
Section: Management Of Immunosuppression With Covid‐19mentioning
confidence: 96%
“…Baricitinib, at therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, thus it has been suggested to be trialed in an appropriated COVID population [6,292]. On the other hand, therapies targeting JAK complexes may interfere with normal anti-viral response including inhibition of IFN-γ activity and may potentially increase the risk of infection and/or reactivation of several viral infectious diseases [293][294][295], including a dose dependent risk for VZV observed for tofacitinib and baricitinib [296]. Thus, their usage should be carefully evaluated.…”
Section: Janus Kinases Inhibitorsmentioning
confidence: 99%